CN101092366A - Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochlorid, processes for preparing thereof - Google Patents
Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochlorid, processes for preparing thereof Download PDFInfo
- Publication number
- CN101092366A CN101092366A CN 200710126398 CN200710126398A CN101092366A CN 101092366 A CN101092366 A CN 101092366A CN 200710126398 CN200710126398 CN 200710126398 CN 200710126398 A CN200710126398 A CN 200710126398A CN 101092366 A CN101092366 A CN 101092366A
- Authority
- CN
- China
- Prior art keywords
- venlafaxine hydrochloride
- type
- venlafaxine
- solvent
- solvate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 100
- 229960004688 venlafaxine Drugs 0.000 title claims abstract description 63
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 title claims abstract description 54
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 title abstract description 7
- QYRYFNHXARDNFZ-UHFFFAOYSA-N venlafaxine hydrochloride Chemical compound [H+].[Cl-].C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 QYRYFNHXARDNFZ-UHFFFAOYSA-N 0.000 claims abstract description 182
- 229960002416 venlafaxine hydrochloride Drugs 0.000 claims abstract description 182
- 239000012453 solvate Substances 0.000 claims abstract description 56
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims abstract description 54
- 239000000203 mixture Substances 0.000 claims abstract description 33
- 238000002360 preparation method Methods 0.000 claims abstract description 17
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 57
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical group CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 53
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 44
- 239000002904 solvent Substances 0.000 claims description 44
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 39
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 39
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 28
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 27
- 238000001035 drying Methods 0.000 claims description 26
- 239000013078 crystal Substances 0.000 claims description 21
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- 238000002425 crystallisation Methods 0.000 claims description 17
- 230000008025 crystallization Effects 0.000 claims description 16
- 239000000010 aprotic solvent Substances 0.000 claims description 13
- XTEGARKTQYYJKE-UHFFFAOYSA-N chloric acid Chemical compound OCl(=O)=O XTEGARKTQYYJKE-UHFFFAOYSA-N 0.000 claims description 13
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 12
- 239000012296 anti-solvent Substances 0.000 claims description 10
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 9
- 238000010438 heat treatment Methods 0.000 claims description 9
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 claims description 7
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 6
- 230000003068 static effect Effects 0.000 claims description 6
- 238000013019 agitation Methods 0.000 claims description 5
- 239000012456 homogeneous solution Substances 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 2
- 230000001476 alcoholic effect Effects 0.000 claims description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical group CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 1
- 238000001640 fractional crystallisation Methods 0.000 claims 1
- 238000010992 reflux Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000002585 base Substances 0.000 description 19
- 239000007787 solid Substances 0.000 description 15
- 230000006837 decompression Effects 0.000 description 14
- 239000000243 solution Substances 0.000 description 13
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 12
- 239000000725 suspension Substances 0.000 description 11
- 229960004756 ethanol Drugs 0.000 description 9
- -1 venlafaxine hydrochlorides Chemical class 0.000 description 9
- 238000005406 washing Methods 0.000 description 9
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 7
- 238000001938 differential scanning calorimetry curve Methods 0.000 description 7
- 239000007789 gas Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 238000007614 solvation Methods 0.000 description 6
- 239000011877 solvent mixture Substances 0.000 description 5
- 239000003513 alkali Substances 0.000 description 4
- 230000017858 demethylation Effects 0.000 description 4
- 238000010520 demethylation reaction Methods 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004807 desolvation Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- FDPIMTJIUBPUKL-UHFFFAOYSA-N pentan-3-one Chemical compound CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- QEEKASZBZSQJIA-UHFFFAOYSA-N chloric acid hydrochloride Chemical compound Cl.O[Cl](=O)=O QEEKASZBZSQJIA-UHFFFAOYSA-N 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000003810 ethyl acetate extraction Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009834 vaporization Methods 0.000 description 1
- 230000008016 vaporization Effects 0.000 description 1
Images
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The present invention relates to novel essentially pure venlafaxine and the process of preparation thereof. The present invention also relates to novel solvate forms of venlafaxine hydrochloride and the process of preparation thereof. Furthermore, the present invention provides a novel process for preparing venlafaxine hydrochloride from venlafaxine; the process comprises the steps of: i) preparing a mixture of venlafaxine with acetone; and ii) exposing the mixture in gaseous hydrochoric acid.
Description
The application be that October 19 calendar year 2001, application number are 01820818.5 the applying date, denomination of invention divides an application for the application for a patent for invention of " crystalline venlafaxine base and new venlafaxine hydrochloride polymorphic form and preparation method thereof ".
The cross-reference of related application
The application requires provisional application sequence number 60/241,577 (submissions on October 19th, 2000), 60/258, the right of priority of 861 (submissions on December 29th, 2000), 60/278,721 (submission on March 26 calendar year 2001) and 60/292,469 (submission on May 21 calendar year 2001).The content of above-mentioned application is all incorporated it into this paper at this by reference.
Background of invention
Venlafaxine (Venlafaxine) with following formula I structure, (±)-1-[2-(dimethylamino)-1-(4-p-methoxy-phenyl) ethyl] hexalin is a first kind antidepressive.Venlafaxine plays a role by the re-uptake that suppresses norepinephrine and thrombotonin, and is the surrogate of tricyclic antidepressants and selectivity reuptake inhibitor.
US patent 4,535,186 (' 186 patent) has been described the method through venlafaxine base intermediate preparation venlafaxine hydrochloride.' 186 patents are all incorporated it into this paper at this by reference.But ' 186 patents do not describe whether the Venlafaxine that it obtained is solid.
In EP0797991 A1, mention, have some venlafaxine hydrochloride polymorphic forms.
In the general introduction benchmark (Summary Basis) of 20-151 number (venlafaxine hydrochloride tablet) and 20-699 number (venlafaxine sustained-release capsule) approval new drug application, three kinds of polymorphic forms of venlafaxine hydrochloride have been mentioned.
We have had now found that a kind of separation Venlafaxine solid novel method.Isolated Venlafaxine is the white crystals form, confirms that through high pressure lipuid chromatography (HPLC) (HPLC) its purity is 99.3% or higher.
We find that adopt a kind of novel method, by venlafaxine hydrochloride, by N, the methylation of N-two demethylation Venlafaxines can make crystalline venlafaxine.
We have found two kinds of new venlafaxine hydrochloride polymorphic forms (called after type i and Type II) and two kinds of new solvate forms (called after type-iii and IV).
We have found to be prepared by venlafaxine base and spirit of salt (HCl) gas the method for venlafaxine hydrochloride in acetone.And found that aforesaid method is used to prepare the purposes of venlafaxine hydrochloride type i and Type II.
Summary of the invention
According to an aspect of the present invention, the present invention relates to pure basically Venlafaxine.
According to a further aspect in the invention, the present invention relates to pure basically venlafaxine hydrochloride.
According to a further aspect in the invention, the invention provides the method for preparing venlafaxine base by venlafaxine hydrochloride.
According to a further aspect in the invention, the invention provides by N, the alkylating of N-two demethylation Venlafaxines prepares the method for venlafaxine base.
According to an aspect of the present invention, the present invention relates to prepare the method for pure basically venlafaxine hydrochloride through the solid Venlafaxine.
According to a further aspect in the invention, the present invention relates to two kinds of new venlafaxine hydrochloride polymorphic forms, the solvate forms of called after type i and Type II and venlafaxine hydrochloride, called after type-iii and type i V.
According to a further aspect in the invention, the invention provides the method for the anhydrous type i of preparation, this method be with compound dissolution in water, and make its precipitation by adding DMF (dimethyl formamide) or MEK (methyl ethyl ketone).
According to a further aspect in the invention, the invention provides a kind of method for preparing the solvate type-iii, this method be with compound dissolution in the protonic solvent such as water, ethanol or methyl alcohol, and make its precipitation by the aprotic solvent that adds such as acetone, ethyl acetate, isopropyl ether or t-butyl methyl ether (MTBE).
According to a further aspect in the invention, the invention provides a kind of method for preparing the solvate type-iii, this method is that compound dissolution is made its precipitation in chloroform and by adding hexane or toluene.
According to a further aspect in the invention, the invention provides a kind of method for preparing the solvate type-iii, this method is a crystalline compounds in dehydrated alcohol or Virahol.
According to a further aspect in the invention, the invention provides a kind of method for preparing the solvate type-iii, this method is by polishing compounds in the aprotic solvent such as ethyl acetate, isopropyl ether or hexane.
According to a further aspect in the invention, the invention provides a kind of method for preparing solvate type i V, this method is by crystalline compounds in DMF (dimethyl formamide) and DMSO (methyl-sulphoxide), perhaps by compound dissolution is made its precipitation in water and by adding DMSO.
According to a further aspect in the invention, the invention provides a kind of method for preparing venlafaxine hydrochloride by venlafaxine base.
According to a further aspect in the invention, the invention provides a kind of method for preparing venlafaxine hydrochloride, comprise the steps: to form Venlafaxine, preferred venlafaxine base, the mixture in acetone, and mixture is exposed in the gaseous hydrogen chloric acid (HCl).
According to a further aspect in the invention, the invention provides a kind of method for preparing venlafaxine hydrochloride, comprise that the homogeneous solution with Venlafaxine/acetone is exposed in the gaseous hydrogen chloric acid (HCl).
According to a further aspect in the invention, the invention provides the method for the homogeneous solution of preparation Venlafaxine in the preferred acetone of the insoluble basically or limited dissolved solution of Venlafaxine.
According to a further aspect in the invention, the invention provides a kind of method for preparing Venlafaxine type i and Type II.
According to a further aspect in the invention, the invention provides a kind of method for preparing venlafaxine hydrochloride, comprise step: 1) preparation Venlafaxine, the mixture (or homogeneous solution) of preferred venlafaxine base and acetone; With 2) mixture is exposed in the gaseous hydrogen chloric acid (HCl).
According to a further aspect in the invention, the invention provides venlafaxine hydrochloride, described venlafaxine hydrochloride is that purity is about 99.92% white crystal.
According to a further aspect in the invention, the invention provides the method for preparing the venlafaxine hydrochloride type i, comprise with acetone and grind venlafaxine hydrochloride, then, under the decompression agitation condition, carry out drying, and crystallization goes out venlafaxine hydrochloride.
According to a further aspect in the invention, the invention provides the venlafaxine hydrochloride type i that makes as follows, described method comprises with acetone grinds venlafaxine hydrochloride, then, under the decompression agitation condition, carry out drying, and crystallization goes out venlafaxine hydrochloride.
According to a further aspect in the invention, the invention provides the venlafaxine hydrochloride type i, described venlafaxine hydrochloride type i is the white crystal of purity about 99.95%.
According to a further aspect in the invention, the invention provides the method for preparing the venlafaxine hydrochloride Type II, comprise with acetone and grind venlafaxine hydrochloride, then, drying under reduced pressure in tray drier (tray), and crystallization goes out venlafaxine hydrochloride.
According to a further aspect in the invention, the invention provides the venlafaxine hydrochloride Type II that makes as follows, described method comprises with acetone grinds venlafaxine hydrochloride, then, and drying under reduced pressure in tray drier, and crystallization goes out venlafaxine hydrochloride.
According to a further aspect in the invention, the invention provides the venlafaxine hydrochloride Type II, described venlafaxine hydrochloride Type II is the white crystal of purity about 99.95%.
The accompanying drawing summary
Fig. 1 represents differential scanning calorimetric (DSC) curve of venlafaxine hydrochloride type i.
Fig. 2 represents the powder x-ray diffraction figure (PXRD) of venlafaxine hydrochloride type i.
Fig. 3 represents the DSC curve of venlafaxine hydrochloride Type II.
Fig. 4 represents the PXRD of venlafaxine hydrochloride Type II.
Fig. 5 represents the DSC curve of venlafaxine hydrochloride type-iii.
Fig. 6 represents the PXRD of venlafaxine hydrochloride type-iii.
Fig. 7 represents the DSC curve of venlafaxine hydrochloride type i V.
Fig. 8 represents the PXRD of venlafaxine hydrochloride type i V.
Fig. 9 represents the PXRD of crystalline venlafaxine base.
Figure 10 is illustrated in spirit of salt (HCl) gas and there is the diagram method that is prepared venlafaxine hydrochloride down by venlafaxine base in acetone.
Detailed Description Of The Invention
This paper uses following abbreviation term: " DMF " refers to dimethyl formamide; " MEK " nail The base ethyl ketone; " MTBE " refers to tert-butyl group methyl ether; " DMSO " refers to methyl-sulfoxide; " DSC " Refer to differential scanning calorimetry; " PXRD " refers to powder x-ray diffraction figure; " IPA " refers to isopropyl Alcohol; " HCl " refers to hydrochloric acid.
I)
The Venlafaxine free alkali
The present invention relates to basically pure Venlafaxine, it is shocking, it can free alkali Form obtain. This Venlafaxine alkali exists with solid crystallization way.
Basically pure Venlafaxine is prepared as follows: NaOH is added the Venlafaxine hydrochloride In the aqueous solution, extract the mixture that obtains with organic solvent. Can use ethyl acetate, heptane, Hexane and composition thereof extracts. Extractant is preferably ethyl acetate. Dry having of merging The machine layer preferably carries out drying with anhydrous sodium sulfate, and evaporation. From hexane or heptane, tie then Crystalline substance goes out residue.
Leach the crystal that obtains, with cold hexane or heptane wash, drying, obtain solid Wen Lafa Suffering, purity are 99.3% or higher. The purity of solid Venlafaxine is generally greater than about 97%, and is excellent Choosing is greater than about 98%, most preferably greater than about 99%.
This solid Venlafaxine further reacts and crystallization with hydrochloric acid, obtains basically pure literary composition The hot hydrochloride of daraf(reciprocal of farad).
The present invention is described further by following embodiment, and these embodiment are used for limiting the scope of the invention anything but.
(10.0 grams, 80.0mmol) (20.0 grams are 63.7mmol) in water (100ml) solution for the venlafaxine hydrochloride of the stirring in the adding ice-water-bath with 32% aqueous sodium hydroxide solution.At ice/stirred in water bath mixture about 30 minutes, with ethyl acetate extraction (3 * 30ml).With the organic layer that anhydrous sodium sulfate drying merges, filter and (water-bath) reduction vaporization under about 50-60 ℃.Resistates is dissolved in the boiling hexane (50ml) cooling in refrigerator (18 ℃).
Leach the crystal that obtains, with cold hexane (20ml) washing, drying under reduced pressure, obtain 15.5 gram (87.7%) white Venlafaxine crystal, it is about 99.3% detecting its purity with HPLC, mp78.3-79.5 ℃.
By N, N-two demethylation venlafaxine hydrochlorides prepare the crystalline venlafaxine free alkali
In room temperature, (2.75 grams 0.022mol) add the N that stirs, and (5.72 grams are 0.02mol) in water (13ml) solution for N-two demethylation venlafaxine hydrochlorides with 32% aqueous sodium hydroxide solution.(4.16 grams, 0.08mol) (3.7 grams 0.044mol) add in this milk sap with 35.8% formalin with 88.5% aqueous formic acid.The mixture backflow that obtains was stirred 8 hours, be cooled to room temperature, be adjusted to pH～11, with heptane (100ml) extraction with 32% aqueous sodium hydroxide solution.
Water (20ml) washing organic extract liquid with dried over sodium sulfate and evaporate two volumes, filters and obtains crystalline venlafaxine base.
II)
Venlafaxine hydrochloride
The invention provides a kind of method of purifying venlafaxine hydrochloride, comprise venlafaxine hydrochloride is alkalized.
The invention provides a kind of method of purifying venlafaxine hydrochloride, further comprise crystalline venlafaxine.
The invention provides a kind of method of purifying venlafaxine hydrochloride, further comprise Venlafaxine and the spirit of salt reaction that will above make, and crystallization, make venlafaxine hydrochloride with higher purity regeneration.The purity of venlafaxine hydrochloride generally greater than about 97%, is preferably greater than 98%, most preferably greater than about 99%.
The method of describing according to US patent 4,535,186 obtains venlafaxine hydrochloride, and this United States Patent (USP) is incorporated this paper by reference into.
III)
Solvate that venlafaxine hydrochloride is new and polymorphic form
The venlafaxine hydrochloride type i
According to an aspect of the present invention, the present invention relates to the new polymorphic form of venlafaxine hydrochloride, its called after type i.This crystal formation is characterised in that: the strong characteristic peak of X-ray occurs 2 θ=about 10.2,15.5,20.3,21.7 ± 0.2 °, strong peak in ° appearance of 2 θ=6.7,13.5,18.2,19.8,22.6,25.6,28.1,35.1 ± 0.2.
The DSC thermogram of type i comprises: because fusing, about 210-213 ℃ endotherm(ic)peak.
The venlafaxine hydrochloride Type II
According to an aspect of the present invention, the present invention relates to the new polymorphic form of venlafaxine hydrochloride, its called after Type II.This crystal formation is characterised in that: the strong characteristic peak of X-ray occurs 2 θ=about 12.8,20.5,21.3 ± 0.2 °, strong peak in ° appearance of 2 θ=6.8,8.5,10.3,13.6,15.6,16.5,19.8,19.9,21.9,25.2,28.7,31.2,31.7,35.3 ± 0.2.
The DSC thermogram of Type II comprises: because fusing, about 210-213 ℃ endotherm(ic)peak; Usually observe phase transformation, produce a peak at about 219-222 ℃ thus.Phase transformation can take place to some extent and may follow the distillation phenomenon.
The venlafaxine hydrochloride type-iii
According to a further aspect in the invention, the present invention relates to the new solvation crystal formation of venlafaxine hydrochloride, its called after type-iii.This crystal formation is characterised in that: the strong characteristic peak of X-ray occurs 2 θ=about 7.4,14.9,26.5 ± 0.2 °, strong peak in 2 θ=about 12.9,16.4,17.5,18.6,18.9,20.5,21.4,38.2 ± 0.2 ° of appearance.
The DSC thermogram of type-iii comprises: because the wide endotherm(ic)peak of desolvation, and the little endotherm(ic)peak in about 180-200 ℃ of scope and because fusing, in about 212 ℃ endotherm(ic)peak.
This solvation form can contain water, methyl alcohol, ethanol or hexane.For containing methyl alcohol or alcoholic acid compound, the drying loss value is about 5.6%-6.0%, and for the compound that contains Virahol, the drying loss value is about 4.6%, and for the compound that contains hexane, the drying loss value is about 5.5%.
These numerical value show: the stoichiometric composition of the about 1/2 molecule methyl alcohol of per molecule venlafaxine hydrochloride or ethanol and 1/4 molecule Virahol.These data are pointed out, have half solvate of ethanol or methyl alcohol and 1/4 solvate of Virahol.
Venlafaxine hydrochloride type i V
According to a further aspect in the invention, the present invention relates to the new solvate crystal formation of venlafaxine hydrochloride, its called after type i V.This crystal formation is characterised in that: have the strong characteristic peak of X-ray 2 θ=about 10.3,20.3 ± 0.2 °, strong peak in 2 θ=about 6.8,13.5,15.6,21.8,27.2,35.2 ± 0.2 ° of existence.
The DSC thermogram of type i V comprises: owing to the wide endotherm(ic)peak of desolvation with owing to fusing, in about 212 ℃ endotherm(ic)peak.
This solvation crystal formation can comprise DMSO or DMF.According to the mensuration of TGA (TGA), for crystalline compound in DMSO, its drying loss value is about 41%, and for crystalline compound in DMF, its drying loss value is about 33%.These numerical value (that is, about 41% and 33%) are corresponding to stoichiometric number-per molecule venlafaxine hydrochloride, 3 molecule DMSO and 2 molecule DMF.In view of the above, we infer that the type i V of solvation can be three solvates of DMSO and two solvates of DMF.
IV)
Preparation crystalline venlafaxine hydrochloride polymorph thing
The invention discloses the method for the different polymorphic forms of preparation venlafaxine hydrochloride.
As can be seen, new polymorphic form (called after type i and Type II) changes acquisition by solvate forms in drying treatment.
As can be seen, formed the form (called after type-iii and type i V) of new solvation by crystallization.
As can be seen, can obtain type i, Type II or their mixture by drying treatment solvate type-iii and IV.By using rotatory evaporator (rotavapor), wherein, drying conditions comprises decompression, continuous swirling powder and carries out mildly heating at about 60 ℃, mainly obtains type i; But, under a few cases, also can obtain the mixture of type i or type i and II.By dry solvent thing form in static baking oven (at about 160 ℃, dry 1/2 hour), type-iii changes Type II into, and type i V changes type i into.
As can be seen, type-iii can be used different solvents, forms solvate as ethanol, methyl alcohol or Virahol.
As can be seen, type i V can form solvate with DMF and DMSO.
Found a kind of method for preparing new solvate type-iii.In the method, venlafaxine hydrochloride is dissolved in such as the protonic solvent of water, ethanol or methyl alcohol (promptly, solvent with hydroxyl [OH]) in, the aprotic solvent of adding such as acetone, ethyl acetate, isopropyl ether or t-butyl methyl ether (promptly, the solvent of no hydroxyl [OH]), make the solvate type-iii.In rotatory evaporator,, further, obtain new polymorphic form I in about 45 minutes of (～10 millibars) dry sample of decompression (or more than) at about 60 ℃.
Find a kind of method, wherein, venlafaxine hydrochloride has been dissolved in the chloroform, in this solution, added DMF or DMSO, made new solvate type-iii.In rotatory evaporator,, further, obtain new polymorphic form I in about 45 minutes of (～10 millibars) dry sample of decompression (or more than) at about 60 ℃.
Direct crystallization in ethanol, Virahol, chloroform, also can make type-iii, in rotatory evaporator, at about 60 ℃, further, obtain new polymorphic form I or the mixture of polymorphic form type i and II in about 45 minutes of (～10 millibars) dry sample of decompression (or more than).
Direct crystallization from DMF and DMSO makes new solvate type i V, at about 60 ℃, further in about 45 minutes of (～10 millibars) dry sample of decompression (or more than), obtains new polymorphic form II or the mixture of polymorphic form type i and II.
Find a kind of method, wherein, venlafaxine hydrochloride has been dissolved in the water, in this solution, added MEK or DMF, made new polymorphic form I.
Found a kind of method, wherein, venlafaxine hydrochloride be dissolved in the methyl alcohol that in solvent: anti-solvent is about 3: 30 ratio, adds ethyl acetate in solution, makes new polymorphic form II.
Method
PXRD
X-ray diffractometer, Philips Generator TW1830
Goniometer PW3020
MPD controls PW3710
Have Cu target anodic X-x ray tube
The monochromator proportional counter
1 ° of divergent slit receives slit 0.2mm, 1 ° of scatter slit
Power supply: 40KV, 30mA
Sweep velocity: 2 °/minute, rank are wide: 0.05 °
TGA
DTG-50，Shimadzu
Example weight: 7-15mg
Temperature range: reach 185 ℃
Rate of heating: 10 ℃/min
DSC
DSC821e，Mettler?Toledo
Example weight: 3-5mg
Temperature range: 30-250 ℃
Rate of heating: 10 ℃/min
Crucible hole count: 3
Embodiment 3
Prepare type-iii and type i with solvent/anti-solvent
Ratio: 0.7ml water: 9.7ml acetone: 3 gram venlafaxine hydrochlorides
Under refluxad, venlafaxine hydrochloride is dissolved in the water, adds acetone.The suspension that forms was refluxed 10 minutes again, at room temperature reveal to put and spend the night.Afterwards, filtering suspension liquid is with the identical solvent mixture washing of about 2ml.The solid that obtains is to crystallize out with type-iii.In rotatory evaporator,, further, obtain type i in dry about 45 minutes of decompression (～10 millibars) (or more than) at about 60 ℃.
Embodiment 4
Prepare solvate III and polymorphic form I with solvent/anti-solvent
Ratio: 3ml methyl alcohol: 9.5ml ethyl acetate: 2.5 gram venlafaxine hydrochlorides
Ratio: 3.8ml methyl alcohol: 2ml isopropyl ether: 3 gram venlafaxine hydrochlorides
Ratio: 3.5ml methyl alcohol: 2ml MTBE:3.1 restrains venlafaxine hydrochloride
Under refluxad, venlafaxine hydrochloride is dissolved in the methyl alcohol, adds ethyl acetate or isopropyl ether or MTBE.The suspension that forms was refluxed 10 minutes again, at room temperature reveal to put and spend the night.Afterwards, filtering suspension liquid is with the identical solvent mixture washing of about 2ml.The solid that obtains is to crystallize out with type-iii.In rotatory evaporator,, further, obtain type i in dry about 45 minutes of decompression (～10 millibars) (or more than) at about 60 ℃.
Embodiment 5
Prepare type-iii and type i/II with solvent/anti-solvent
Ratio: 12ml chloroform: 5ml hexane: 2.5 gram venlafaxine hydrochlorides
Ratio: 6ml ethanol: 9ml ethyl acetate: 3 gram venlafaxine hydrochlorides
Ratio: 12ml chloroform: 5ml toluene: 2.6 gram venlafaxine hydrochlorides
Under refluxad, venlafaxine hydrochloride is dissolved in the solvent, adds anti-solvent.The suspension that forms was refluxed 10 minutes again, at room temperature reveal to put and spend the night.Afterwards, filtering suspension liquid is with the identical solvent mixture washing of about 2ml.The solid that obtains is to crystallize out with type-iii.In rotatory evaporator,, further, obtain Type II or type i or their mixture in dry about 45 minutes of decompression (～10 millibars) (or more than) at about 60 ℃.
Embodiment 6
Prepare type-iii and type i/Type II by direct crystallization
Under refluxad, venlafaxine hydrochloride (2 gram) is dissolved in ethanol (8ml) or the Virahol (10ml).Solution at room temperature placed spend the night.Leach crystallisate, with the washing of 2ml same solvent.The solid that obtains is to crystallize out with type-iii.In rotatory evaporator,, further, obtain Type II or type i or their mixture in dry about 45 minutes of decompression (～10 millibars) (or more than) at about 60 ℃.
Embodiment 7
Prepare type i V and type i/II by direct crystallization
Under refluxad, venlafaxine hydrochloride (2 gram) is dissolved among DMF or the DMSO (8ml).Solution at room temperature placed spend the night.Leach crystallisate, with the washing of 2ml same solvent.The solid that obtains is to crystallize out with type-iii.In rotatory evaporator,, further, obtain Type II or type i or their mixture in dry about 45 minutes of decompression (～10 millibars) (or more than) at about 60 ℃.
Prepare type i with solvent/anti-solvent
Ratio: 0.5ml water: 13ml DMF:3 restrains venlafaxine hydrochloride
Ratio: 0.5ml water: 13ml DMSO:3.1 restrains venlafaxine hydrochloride
Under refluxad, venlafaxine hydrochloride is dissolved in the water, adds anti-solvent.The suspension that forms was refluxed 10 minutes again, at room temperature reveal to put and spend the night.Afterwards, filtering suspension liquid is with the identical solvent mixture washing of about 2ml.The solid that obtains is to crystallize out with type i.In rotatory evaporator,, further, obtain type i in dry about 45 minutes of decompression (～10 millibars) (or more than) at about 60 ℃.
Embodiment 9
Prepare Type II with solvent/anti-solvent
Ratio: 10ml methyl alcohol: 30ml ethyl acetate: 3 gram venlafaxine hydrochlorides
At approximately 0-5 ℃, venlafaxine hydrochloride is dissolved in the methyl alcohol, add anti-solvent.The suspension that forms was stirred 30 minutes.Afterwards, filtering suspension liquid is with the identical solvent mixture washing of 2ml.The solid that obtains is to crystallize out with Type II.In rotatory evaporator,, further, obtain Type II in dry about 45 minutes of decompression (～10 millibars) (or more than) at about 60 ℃.
Prepare Type II by heating type-iii in static baking oven
The type-iii sample was placed in about 160 ℃ static baking oven about 1/2 hour.
The polymorphic form that obtains is a Type II.
Embodiment 11
Prepare type i by heating type i V in static baking oven
Type i V sample was placed in about 160 ℃ static baking oven about 1/2 hour.The polymorphic form that obtains is a type i.
Prepare type-iii by grinding type i
In isopropyl ether, hexane or ethyl acetate (8ml), the sample of venlafaxine hydrochloride type i (2g) was under refluxad ground about 1 hour or at room temperature grind and spend the night.The gained solid contains the type-iii of solvation.
V) in acetone, prepare venlafaxine hydrochloride by venlafaxine base and HCl gas and the invention provides a kind of method for preparing venlafaxine hydrochloride.This method comprises is exposed in the gaseous hydrogen chloric acid (HCl) venlafaxine base.
The diagram reaction formula that is prepared venlafaxine hydrochloride by venlafaxine base is listed in Figure 10.
Embodiment 13
Preparation venlafaxine hydrochloride crude product
Prepare the required reagent of venlafaxine hydrochloride and solvent is summarized in the table 1 by venlafaxine base.
Table 1: reagent and solvent
1. venlafaxine base 27.7 restrains 100mmol 1.0 equivalents
2.HCl, gas
3. acetone 846 restrains
The theoretical yield of product (that is venlafaxine hydrochloride) be about 31.34 the gram (that is, 100mmol).
In having 1 liter of double jacket reactor of mechanical stirrer, thermometer, pH-electrode and the dark pipe of PTFE, pack into venlafaxine base (about 27.7 gram) and acetone (about 526 restrain).At the stirring at room mixture about 20 minutes, until forming homogeneous solution.
At about 10 ℃, under intense agitation, with gas chlorination hydracid solution, making pH is about 2.0.With the suspension that obtains about 10 ℃ of stir abouts 2 hours.
Leach sedimentary crystal, wash on strainer with cold acetone (about 120 gram), and at about 50 ℃ of (water-bath) drying under reduced pressure to constant weight, obtain about 29.57 gram (about 94.4%) venlafaxine hydrochloride white crystals, analyze through HPLC, its purity is about 99.9 2%.
Preparation venlafaxine hydrochloride (type i)
Thick venlafaxine hydrochloride (about 15.0 grams) was ground about 1 hour and ground about 1 hour at about 0 ℃ at about 60 ℃ with acetone (about 60.0 grams), filter, wash on strainer with cold acetone (about 120 grams), and in about 50 ℃ (water-baths), under agitation condition, drying under reduced pressure obtains about 14.8 gram (about 93.2%) venlafaxine hydrochloride white crystals to constant weight, analyze through HPLC, its purity is about 99.95%.
Preparation venlafaxine hydrochloride (Type II)
Thick venlafaxine hydrochloride (about 15.0 grams) was ground about 1 hour and ground about 1 hour at about 0 ℃ at about 60 ℃ with acetone (about 60.0 grams), filter, wash on strainer with cold acetone (about 120 grams), and in about 50 ℃ (water-baths), drying under reduced pressure is to constant weight in tray drier (tray), obtain about 14.8 gram (about 93.2%) venlafaxine hydrochloride white crystals, analyze through HPLC, its purity is about 99.95%.
Preparation venlafaxine hydrochloride type i
Venlafaxine base (1Kg) is dissolved in the Virahol (6L).At～20 ℃, spirit of salt (gas) bubbling is passed through, until pH=7.The reacting by heating mixture obtains settled solution, is cooled to 10 ℃ gradually.Leach throw out, with washed with isopropyl alcohol and vacuum-drying.
The invention is not restricted in the specific embodiments scope described herein.In fact, book and accompanying drawing according to the above description, those skilled in the art can understand the various variation schemes of making based on the present invention.Such variation scheme will fall into the protection domain of claim.
Claims (78)
1. the venlafaxine hydrochloride type i is characterized in that, powder X-ray diffraction peak appears at 2 θ=10.2,15.5,20.3,21.7 ± 0.2 °.
2. the venlafaxine hydrochloride type i is characterized in that, powder X-ray diffraction peak appears at 2 θ=6.7,10.2,13.5,15.5,18.2,19.8,20.3,21.7,22.6,25.6,28.1,35.1 ± 0.2 °.
3. the venlafaxine hydrochloride Type II is characterized in that, powder X-ray diffraction peak appears at 2 θ=12.8,20.5,21.3 ± 0.2 °.
4. venlafaxine hydrochloride type i I, it is characterized in that powder X-ray diffraction peak appears at 2 θ=6.8,8.5,10.3,12.8,13.6,15.6,16.5,19.1,19.9,20.5,21.3,21.9,25.2,28.7,31.2,31.7,35.3 ± 0.2 °.
5. the venlafaxine hydrochloride type-iii is characterized in that, powder X-ray diffraction peak appears at 2 θ=7.4,14.9,26.5 ± 0.2 °.
6. the venlafaxine hydrochloride type-iii is characterized in that, powder X-ray diffraction peak appears at 2 θ=7.4,12.9,14.9,16.4,17.5,18.6,18.9,20.5,21.4,26.5,38.2 ± 0.2 °.
7. the venlafaxine hydrochloride solvate is characterized in that, powder X-ray diffraction peak appears at 2 θ=7.4,14.9,26.5 ± 0.2 °.
8. the venlafaxine hydrochloride solvate is characterized in that, powder X-ray diffraction peak appears at 2 θ=7.4,12.9,14.9,16.4,17.5,18.6,18.9,20.5,21.4,26.5,38.2 ± 0.2 °.
9. the venlafaxine hydrochloride of the arbitrary claim of claim 7-8, wherein solvate is selected from ethylate, methylate and Virahol thing.
10. venlafaxine hydrochloride type i V is characterized in that, powder X-ray diffraction peak appears at 2 θ=10.3,13.5,15.6,20.3 ± 0.2 °.
11. venlafaxine hydrochloride type i V is characterized in that, powder X-ray diffraction peak appears at 2 θ=6.8,10.3,13.5,15.6,20.3,21.8,27.2,35.2 ± 0.2 °.
12. the venlafaxine hydrochloride solvate is characterized in that, powder X-ray diffraction peak appears at 2 θ=10.3,13.5,15.6,20.3 ± 0.2 °.
13. the venlafaxine hydrochloride solvate is characterized in that, powder X-ray diffraction peak appears at 2 θ=6.8,10.3,13.5,15.6,20.3,21.8,27.2,35.2 ± 0.2 °.
14. the venlafaxine hydrochloride of the arbitrary claim of claim 12-13, wherein solvate contains the solvent that is selected from DMSO and DMF.
15. a method for preparing the product of arbitrary claim among the claim 5-8, this method comprise venlafaxine hydrochloride is dissolved in the protonic solvent, and makes its crystallization by adding aprotic solvent.
16. according to the method for claim 15, wherein protonic solvent is selected from water, methyl alcohol and ethanol.
17. according to the method for claim 15, wherein aprotic solvent is selected from acetone, ethyl acetate, isopropyl ether and MTBE.
18. a method for preparing the product of arbitrary claim among the claim 5-8, this method are included in crystalline venlafaxine hydrochloride in the protonic solvent.
19. according to the method for claim 18, wherein protonic solvent is selected from ethanol and Virahol.
20. a method for preparing the product of arbitrary claim among the claim 10-13, this method are included in crystalline venlafaxine hydrochloride in the aprotic solvent.
21. according to the method for claim 20, wherein aprotic solvent is selected from DMF and DMSO.
22. a method for preparing the venlafaxine hydrochloride type i comprises venlafaxine hydrochloride is dissolved in the water, and makes its crystallization by adding aprotic solvent.
23. according to the method for claim 22, wherein aprotic solvent is selected from MEK and DMF.
24. a method for preparing the venlafaxine hydrochloride Type II comprises venlafaxine hydrochloride is dissolved in the mixture of protonic solvent and aprotic solvent.
25. according to the method for claim 24, wherein protonic solvent is a methyl alcohol.
26. according to the method for claim 24, wherein aprotic solvent is an ethyl acetate.
27. according to the method for claim 24, wherein solvent: anti-solvent: venlafaxine hydrochloride is 10ml: 30ml: 3 grams.
28. a method, the product of arbitrary claim among the wherein dry claim 5-8 is to obtain venlafaxine hydrochloride type i, venlafaxine hydrochloride Type II or its mixture.
29. a method, the product of arbitrary claim among the wherein dry claim 10-13 is to obtain venlafaxine hydrochloride type-iii, venlafaxine hydrochloride type i V or its mixture.
30. a method for preparing the product of arbitrary claim among the claim 5-8, this method comprise venlafaxine hydrochloride is dissolved in the chloroform, makes its crystallization by adding hexane or toluene.
31. a method for preparing the product of arbitrary claim among the claim 5-8, this method comprise under refluxad, grind venlafaxine hydrochloride at least 1 hour in aprotic solvent.
32. a method for preparing the product of arbitrary claim among the claim 5-8, this method comprise at room temperature, grind venlafaxine hydrochloride at least about 20 hours in aprotic solvent.
33. a method for preparing venlafaxine hydrochloride comprises step:
1) mixture of preparation Venlafaxine in acetone; With
2) mixture is exposed in the gaseous hydrogen chloric acid.
34. according to the method for claim 33, wherein Venlafaxine is a venlafaxine base.
35. according to the method for claim 33, wherein mixture is the homogeneous solution of Venlafaxine.
36. the venlafaxine hydrochloride that makes by the method for claim 33.
37. according to the venlafaxine hydrochloride of claim 36, wherein venlafaxine hydrochloride is that purity is about 99.92% white crystal.
38. a method for preparing the venlafaxine hydrochloride type i comprises with acetone and grinds venlafaxine hydrochloride, carries out drying under reduced pressure then under agitation condition.
39. the venlafaxine hydrochloride type i that makes according to the method for claim 38.
40. according to the venlafaxine hydrochloride type i of claim 39, wherein the venlafaxine hydrochloride type i is that purity is about 99.95% white crystal.
41. a method for preparing the venlafaxine hydrochloride Type II comprises with acetone and grinds venlafaxine hydrochloride, then drying under reduced pressure in tray drier.
42. the venlafaxine hydrochloride Type II that makes according to the method for claim 41.
43. according to the venlafaxine hydrochloride Type II of claim 41, wherein the venlafaxine hydrochloride Type II is that purity is about 99.95% white crystal.
44. crystalline venlafaxine hydrochloride solvate, wherein the venlafaxine hydrochloride solvate contains solvent.
45. according to the crystalline venlafaxine hydrochloride solvate of claim 44, wherein venlafaxine hydrochloride solvate crystalline form is a type-iii.
46. according to the crystalline venlafaxine hydrochloride solvate of claim 44, wherein venlafaxine hydrochloride solvate crystalline form is type i V.
47. according to the crystalline venlafaxine hydrochloride solvate type-iii of claim 45, wherein solvent is selected from water, ethanol, methyl alcohol and Virahol.
48. according to the crystalline venlafaxine hydrochloride solvate type-iii of claim 45, wherein the solvate crystalline form contains about 6.0% methanol solvate of the 5.6%-that has an appointment.
49. according to the crystalline venlafaxine hydrochloride solvate type-iii of claim 45, wherein the solvate crystalline form contains about 6.0% alcohol solvent of the 5.6%-that has an appointment.
50. according to the crystalline venlafaxine hydrochloride solvate type-iii of claim 45, wherein the solvate crystalline form contains 4.6% Virahol of having an appointment.
51. according to the crystalline venlafaxine hydrochloride solvate type-iii of claim 45, wherein the solvate crystalline form contains 5.5% hexane solvent of having an appointment.
52. according to the crystalline venlafaxine hydrochloride solvate type i V of claim 46, wherein solvent is selected from DMSO and DMF.
53. according to the crystalline venlafaxine hydrochloride solvate type i V of claim 52, wherein the solvate crystalline form contains the 41%DMSO solvent of having an appointment.
54. according to the crystalline venlafaxine hydrochloride solvate type i V of claim 52, wherein the solvate crystalline form contains the 33%DMF solvent of having an appointment.
55. crystalline venlafaxine hydrochloride solvate type-iii, wherein the type III contains and is selected from methyl alcohol and alcoholic acid solvent.
56. according to the crystalline venlafaxine hydrochloride solvate type-iii of claim 55, wherein the amount of solvent satisfies following stoichiometric ratio: per molecule venlafaxine hydrochloride 1/2 molecular solvent.
57. crystalline venlafaxine hydrochloride solvate type-iii, wherein the type III contains isopropanol solvent, and the amount of solvent satisfies following stoichiometric ratio: per molecule venlafaxine hydrochloride 1/4 molecular solvent.
58. crystalline venlafaxine hydrochloride solvate type i V, wherein the type IV contains solvent DMSO, and the amount of solvent satisfies following stoichiometric ratio: per molecule venlafaxine hydrochloride 3 molecular solvent.
59. crystalline venlafaxine hydrochloride solvate type i V, wherein the type IV contains solvent DMF, and the amount of solvent satisfies following stoichiometric ratio: per molecule venlafaxine hydrochloride 2 molecular solvent.
60. a method for preparing the venlafaxine hydrochloride type i comprises step:
A) mixture of preparation Venlafaxine in Virahol; With
B) mixture is exposed in the gaseous hydrogen chloric acid.
61. according to the method for claim 60, wherein exposing step is carried out at about 20 ℃.
62., also comprise the steps: to make the crystallization of venlafaxine hydrochloride type i by heating cooling mixture then according to the method for claim 60.
63. according to the method for claim 62, wherein heated mixt forms settled solution.
64., wherein mixture is cooled to gradually about 10 ℃ according to the method for claim 62.
65. a method for preparing the polymorphic form of venlafaxine hydrochloride, described venlafaxine hydrochloride polymorphic form is selected from the mixture of type i, Type II and type i and II, and this method comprises the steps:
A) crystalline venlafaxine hydrochloride from Virahol;
B) venlafaxine hydrochloride of fractional crystallization; With
C) dry isolating venlafaxine hydrochloride obtains the polymorphic form of venlafaxine hydrochloride.
66. according to the method for claim 65, wherein the venlafaxine hydrochloride polymorphic form is a type i.
67. according to the method for claim 65, wherein the venlafaxine hydrochloride polymorphic form is a Type II.
68. according to the method for claim 65, wherein the venlafaxine hydrochloride polymorphic form is the mixture of type i and Type II.
69. according to the method for claim 65, wherein crystallisation step comprises the steps:
A) aqueous isopropanol of preparation venlafaxine hydrochloride;
B) heat the reflux temperature of this solution to Virahol; With
C) solution with heating is cooled to room temperature.
70., wherein carried out described cooling step yesterday by the solution of heating is at room temperature placed according to the method for claim 69.
71. according to the method for claim 65, wherein the venlafaxine hydrochloride by filtering for crystallizing carries out separating step.
72., also comprise step with washed with isopropyl alcohol crystalline venlafaxine hydrochloride according to the method for claim 71.
73. according to the method for claim 65, wherein the crystalline venlafaxine hydrochloride is the venlafaxine hydrochloride type-iii.
74., wherein carry out drying step at about 60 ℃ according to the method for claim 67.
75., wherein under about 10 millibars reduced pressure, carry out drying step according to the method for claim 74.
76. according to the method for claim 75, wherein drying step carried out about 45 minutes.
77. according to the method for claim 68, wherein drying step carries out at about 160 ℃.
78. according to the method for claim 77, wherein drying step carried out in static baking oven about 0.5 hour.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24157700P | 2000-10-19 | 2000-10-19 | |
| US60/241577 | 2000-10-19 | ||
| US60/258861 | 2000-12-29 | ||
| US60/278721 | 2001-03-26 | ||
| US60/292469 | 2001-05-21 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA018208185A Division CN1620420A (en) | 2000-10-19 | 2001-10-19 | Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101092366A true CN101092366A (en) | 2007-12-26 |
Family
ID=38990827
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200710126398 Pending CN101092366A (en) | 2000-10-19 | 2001-10-19 | Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochlorid, processes for preparing thereof |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN101092366A (en) |
| ZA (1) | ZA200302768B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102212014A (en) * | 2010-04-09 | 2011-10-12 | 江苏豪森医药集团有限公司 | Crystal form of O-demethyl-venlafaxine glutamate, preparation method and medicinal application thereof |
| CN103382159A (en) * | 2013-08-16 | 2013-11-06 | 成都倍特药业有限公司 | Venlafaxine hydrochloride preparation method |
| CN103483210A (en) * | 2012-06-13 | 2014-01-01 | 成都弘达药业有限公司 | New compound and preparation method thereof |
-
2001
- 2001-10-19 CN CN 200710126398 patent/CN101092366A/en active Pending
-
2003
- 2003-04-09 ZA ZA200302768A patent/ZA200302768B/en unknown
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102212014A (en) * | 2010-04-09 | 2011-10-12 | 江苏豪森医药集团有限公司 | Crystal form of O-demethyl-venlafaxine glutamate, preparation method and medicinal application thereof |
| CN102212014B (en) * | 2010-04-09 | 2013-12-25 | 江苏豪森医药集团有限公司 | Crystal form of O-demethyl-venlafaxine glutamate, preparation method and medicinal application thereof |
| CN103483210A (en) * | 2012-06-13 | 2014-01-01 | 成都弘达药业有限公司 | New compound and preparation method thereof |
| CN103483210B (en) * | 2012-06-13 | 2016-01-13 | 成都弘达药业有限公司 | A kind of new compound and preparation method thereof |
| CN103382159A (en) * | 2013-08-16 | 2013-11-06 | 成都倍特药业有限公司 | Venlafaxine hydrochloride preparation method |
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200302768B (en) | 2007-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008239629A (en) | Novel polymorph of venlafaxine hydrochloride and method for preparing it | |
| EP3248983B1 (en) | Crystal form a of obeticholic acid and preparation method therefor | |
| US20080167498A1 (en) | Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof | |
| WO2017097275A1 (en) | Solid forms of (2r,4s)-5-(biphenyl-4-yl)-4-[(3-carboxypropionyl)amino]-2- -methylpentanoic acid ethyl ester, its salts and a preparation method | |
| MX2012011821A (en) | Methods for producing viloxazine salts and novel polymorphs thereof. | |
| CN107531636A (en) | The preparation method of QAB-149 or its salt | |
| CN101092366A (en) | Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochlorid, processes for preparing thereof | |
| CZ20014050A3 (en) | Process for preparing (1R,2S,4R)-(-)-2[(2 -{N,N-dimethylamino}-ethoxy)]-2-[phenyl]-1,7,7-tri-[methyl]-bicyclo[2,2,l]heptane and pharmaceutically acceptable acid addition salts thereof | |
| US20210323929A1 (en) | Purified Detomidine, Process of Preparing and Methods of Use | |
| AU2005209382B2 (en) | Method for producing a 2-(ethoxymethyl)tropane derivative | |
| JP2008531510A (en) | Phosphate salt of 6-dimethylaminomethyl-1- (3-methoxyphenyl) -1,3-dihydroxy-cyclohexane compound | |
| CN107383010A (en) | A kind of compound and preparation method thereof | |
| WO2009118758A2 (en) | Novel crystalline forms of desvenlafaxine succinate | |
| CN115819412A (en) | Synthetic method of N-heterocyclic BET bromodomain inhibitor and intermediate thereof | |
| EP4219443A1 (en) | Method for preparing intermediate for synthesis of sphingosine-1-phosphate receptor agonist | |
| WO2009027766A2 (en) | New crystalline solid forms of o-desvenlafaxine base | |
| WO2019072864A1 (en) | Process for the preparation of agomelatine in crystalline form | |
| PL208977B1 (en) | The manner of obtaining of o-hydroxybenzyloamines | |
| JPH0580461B2 (en) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20071226 |